Get the Stockscreener App
910.95
3.34%
29.44
After Hours:
909.99
-0.96
-0.11%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corp stock is traded at $910.95, with a volume of 616.57K.
It is up +3.34% in the last 24 hours and up +4.83% over the past month.
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$881.51
Open:
$900
24h Volume:
616.57K
Relative Volume:
0.63
Market Cap:
$106.21B
Revenue:
$403.43B
Net Income/Loss:
$5.10B
P/E Ratio:
23.68
EPS:
38.4657
Net Cash Flow:
$5.41B
1W Performance:
+0.33%
1M Performance:
+4.83%
6M Performance:
-3.18%
1Y Performance:
+28.05%
1-Day Range:
$893.38
$912.00
1-Week Range:
$874.31
$912.00
52-Week Range:
$687.68
$999.00
Mckesson Corp Stock (MCK) Company Profile
Name
Mckesson Corp
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK vs COR, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCK
Mckesson Corp
|
910.95 | 102.78B | 403.43B | 5.10B | 5.41B | 38.47 |
COR
Cencora Inc
|
326.23 | 61.36B | 328.68B | 2.55B | 1.56B | 13.03 |
CAH
Cardinal Health Inc
|
234.89 | 54.56B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
88.93 | 9.85B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
0.8018 | 718.95M | 14.85M | -136.07M | 7.25M | -0.4726 |
Mckesson Corp Stock (MCK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Dec-04-24 | Resumed | Mizuho | Neutral |
| Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-05-24 | Reiterated | Leerink Partners | Outperform |
| Aug-08-24 | Reiterated | Mizuho | Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| Jul-06-22 | Downgrade | Argus | Buy → Hold |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-02-21 | Reiterated | Barclays | Overweight |
| Nov-02-21 | Reiterated | BofA Securities | Buy |
| Nov-02-21 | Reiterated | Evercore ISI | Outperform |
| Nov-02-21 | Reiterated | Jefferies | Buy |
| Mar-30-21 | Upgrade | Argus | Hold → Buy |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
| May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-22-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Oct-26-18 | Reiterated | Barclays | Equal Weight |
| Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-02-18 | Reiterated | Mizuho | Neutral |
| Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corp Stock (MCK) Latest News
Lawsuits Over McKesson Voice-Phishing Attack Points to Ongoing Risk in Healthcare Sector - Law.com
McKesson stock heads into the open after a 1.2% drop - ad-hoc-news.de
McKesson (MCK) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
McKesson Corp. stock underperforms Thursday when compared to competitors - MarketWatch
McKesson Corp (MCK) Insider Sale: SVP, Controller & CAO Rutledge Napoleon B JR Sells 111 Shares - GuruFocus
McKesson (MCK) Plans A $2.25b Deal, Is The Stock Fully Valued? - simplywall.st
McKesson Senior VP Napoleon Rutledge Jr. Sells 111 Shares via 10b5-1 Trading Plan - Kalkine Media
ShinyHunters expose 6.4M in attack on medical supplier McKesson - The Register
McKesson stock heads into the open after a 1.5 percent slide - ad-hoc-news.de
Why Is McKesson (NYSE:MCK) Stock In Focus Today? - Kalkine Media
McKesson (NYSE:MCK): Is the Cyber Risk Overpriced? - Kalkine Media
McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
McKesson Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates - Yahoo Finance
McKesson at wells fargo healthcare conference: growth, deal push - investing.com
McKesson Corp's negligence caused a data breach, a new class action lawsuit claims - claimdepot.com
Novocure Reports Patient Data Exposure in Cybersecurity Incident - Zacks Investment Research
McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy - Yahoo Finance
McKesson Stock (MCK) Opinions on Recent Data Leak and Market Dynamics - Quiver Quantitative
Mckesson Stock Price Forecast. Should You Buy MCK? - StockInvest.us
McKesson Owns Antitrust Claims, Not Rite Aid, Judge Finds - Law360
McKesson Corp. stock underperforms Friday when compared to competitors - MarketWatch
McKesson Corp (MCK) Stock Price, Quote, News & History - Benzinga
McKesson Data Breach: Investigation Ongoing - Claim Depot
Why Is McKesson (MCK) Up 5.7% Since Last Earnings Report? - finance.yahoo.com
McKesson Stock: Is MCK Outperforming the Healthcare Sector? - Barchart.com
Mckesson Corporation (MCK) News, Articles, Events & Latest Updates - Stocktwits
McKesson Corp. stock outperforms competitors on strong trading day - MarketWatch
McKesson confirms data theft in cyberattack involving third-party apps - finance.yahoo.com
Mckesson Corp Stock (MCK) Moved Up by 3.13% on Sep 1: Key Drivers Unveiled - tradingkey.com
McKesson data breach exposes prescribing physicians and their patients to fallout from a third-party attack - Medical Economics
Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today - Yahoo Finance
ShinyHunters Threatens to Leak Millions of McKesson Records - BankInfoSecurity
McKesson Hit by Cyberattack Affecting 284M Patient Records - Medical Device and Diagnostic industry
McKesson Okta and Cloud Services Breach Analysis: ShinyHunters Vishing Attack Leads to Major Healthcare Data Exfiltration - Rescana
McKesson Corporation: Ademi LLP Investigates Claims for Damages - GlobeNewswire
Mckesson CorpDiscovers Cybersecurity Incident Affecting Information Systems On August 25, 2026SEC Filing - TradingView
8 things to know: Drug distribution giant to buy Maryland firm for $2.25B - The Business Journals
McKesson Corporation (MCK) Doubles Down on Healthcare Growth With Precision Medicine Acquisition - Yahoo Finance
Amid layoffs including at Rx Savings in OP, parent McKesson plans $2.25B acquisition - The Business Journals
What Does McKesson (MCK) Gain From Its Push Into Oncology And Clinical Research? - Yahoo Finance
McKesson to acquire Precision Medicine Group for $2.25bn - finance.yahoo.com
McKesson Corp (MCK) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 87/100 - GuruFocus
McKesson Snags Precision Medicine Group In $2.25B Deal - Law360
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now - TradingView
McKesson to acquire Precision Medicine Group - Chain Drug Review
Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation? - Eastern Progress
Mckesson Corp Stock (MCK) Moved Up by 3.13% on Aug 21: A Full Analysis - TradingKey
McKesson gains as investors lean on strong earnings backdrop and recent guidance lift - Quiver Quantitative
McKesson (MCK) Stock May Trade At A Discount As Cash Flow Holds Up - Yahoo Finance
McKesson Corp. stock outperforms competitors despite losses on the day - MarketWatch
Mckesson Corp Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
4.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):